Revista Asociación de Cirujanos Guatemala Revista 2019 | Page 55

Síndromes de Hipersecreción Hormonal
Referencias
1. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N.
Epidemiology of acromegaly: review of popula-
tion studies. Pituitary 2017; 20:4-9.
2. Caron P, Brue T, Raverot G, et al. Signs and symp-
toms of acromegaly at diagnosis: the physician’s
and the patient’s perspectives in the ACRO-PO-
LIS study. Endocrine 2019; 63:120-129.
3. Peñalonzo MA, Aguilera L, Pineda M, et al. Hi-
perprolactinemia. Etiología, diagnóstico y ma-
nejo. Endocrinología, diabetes y metabolismo
2006; 5:7-15.
4. Shlomo M, et al. Diagnosis and treatment of
hyperprolactinemia: An Endocrine Society Cli-
nical Practice Guideline. J Endocrinol Metabol
2011; 96:273-288.
5. Schlechte J, Dolan K, Serman B, et al. The natural
history of untreated hyperprolactinemia: a pros-
pective analysis. J Clin Endocrinol Metab 1989;
68:412-418.
6. Casanueva F, et al. Guidelines of the Pituitary
Society for the diagnosis and management of
prolactinomas. Clinical Endocrinology 2006;
65:265-273.
7. Davies, L., & Welch, H. G. Increasing Incidence of
Thyroid Cancer in the United States, 1973-2002.
JAMA 2016; 295(18):7–10.
8. Haugen BR, Alexander EK, Bible KC, et al. 2015
American thyroid association management gui-
delines for adult patients with thyroid nodules
and differentiated thyroid cancer: the Ameri-
can thyroid association guidelines task force on
thyroid nodules and differentiated thyroid can-
cer. Thyroid 2016;26(1): 1e133.
9. Myauchi A, Ito Y. Conservative Surveillance Ma-
nagement of Low-Risk Papillary Microcarcino-
ma. Endocrinol Metabol Clinics 2019; 48:215-
226.
10. Rivera M, Aguilera L, Peñalonzo M. Resultados
del tratamiento quirúrgico del Hiperparatiroi-
dismo Primario en un país en vías de desarrollo.
Rev Guatem Cir 2017; 23:16-23.
11. Douma S, Petidis K, Doumas M, Papaefthimiou
P, Triantafyllou A, Kartali N, et al. Prevalence of
primary hyperaldosteronism in resistant hyper-
tension: a ret- rospective observational study.
Lancet 2008; 371:1921–1926.
12. Rossi GP, Bernini G, Caliumi C, Desideri G, Fa-
bris B, Ferri C, et al. A prospective study of the
prevalence of primary aldosteronism in 1,125
hypertensive patients. J Am Coll Cardiol 2006;
48:2293–2300.
13. Mulatero P, Stowasser M, Loh KC, Fardella CE,
Gordon RD, Mosso L, et al. Increased diagnosis
of primary aldosteronism, including surgically
cor- rectable forms, in centers from five conti-
nents. J Clin Endocrinol Metab 2004; 89:1045–
1050.
14. 14. Williams TA, Lenders JWM, Mulatero P, Bu-
rrello J, Rottenkolber M, Adolf C, et al. Outco-
mes after adrenalectomy for unilateral primary
aldosteronism: an international consensus on
outcome measures and analysis of remission ra-
tes in an international cohort. Lancet Diabetes
Endocrinol 2017; 5:689–699.
15. 15. Funder JW, Carey RM, Mantero F, Murad
MH, Reincke M, Shibata H, et al. The manage-
ment of primary aldosteronism: case detection,
diagnosis, and treatment: an Endocrine Society
clinical practice guideline. J Clin Endocrinol Me-
tab 2016; 101:1889–1916.
16. 16. Ruhle B, White M, Alsafran S, et al. Keeping
primary aldosteronism in mind: Deficiencies in
screening at-risk hypertensives. Surgery 2019;
165:221–227.
17. 17. Wang H, Jepegnanam Ch. Recognition and
management of phaeochromocytoma and para-
ganglioma. Anaesthesia and Intensive Care Med
2017; 18 (10):496-501.
Rev Guatem Cir Vol 25 (2019)
51